Evaluation of cyclodextrin solubilization of drugs.

By T. Loftsson, Dagný Hreinsdôttir, M. Másson. International journal of pharmaceutics, 2005

646 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Strategies to Address Low Drug Solubility in Discovery and Development (2013, methodology): “Further evidence that cholesterol-HP-b-CD complexes may have intrinsic solubilization properties is apparent in studies showing an increase in cyclosporine A solubilization by HP-b-CD on the addition of cholesterol (Loftsson et al., 2002, 2005).”
Cyclodextrins as pharmaceutical solubilizers. (2007, methodology): “pointed out that generally the y-intercept values derived from phase–solubility analysis (or [D]int) are good estimates for Do but only in cases where the solubility of the drug is ≥1 mM [76].”
Characterization and Applications of New Hyper-Cross-Linked Cyclodextrins (2009, background): “The complexation mechanism does not involve covalent bonds and the main driving force of complex formation is the release of enthalpy-rich water molecules from the cyclodextrin cavity [1].”
Pharmaceutical applications of cyclodextrins: basic science and product development (2010, methodology): “Partly based on data from Loftsson et al.([54,122]) 2-Hydroxypropyl-b-cyclodextrin (HPbCD); randomly methylated b-cyclodextrin (RMbCD); sulfobutylether b-cyclodextrin sodium salt (SBEbCD).”